Neuroblastoma screening does not reduce mortalityBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7342.867/a (Published 13 April 2002) Cite this as: BMJ 2002;324:867
- Annette Tuffs
Two studies from Canada and Germany published last week provide clear evidence that children aged 1 year or younger should not be screened for neuroblastoma, because mortality is not reduced by mass screening (New England Journal of Medicine 2002;346:1041-6 and 1047-53).
On the contrary, screening may have adverse effects, the researchers say, because it detects early cases of the tumour that probably would have remitted spontaneously without treatment. The German study reported three deaths that were due to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial